Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $13,816.33 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Robert Arthur Harrington sold 253 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $54.61, for a total value of $13,816.33. Following the completion of the transaction, the director now owns 15,516 shares of the company’s stock, valued at $847,328.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Robert Arthur Harrington also recently made the following trade(s):

• On Monday, June 3rd, Robert Arthur Harrington sold 1,580 shares of Cytokinetics stock. The shares were sold at an average price of $48.64, for a total value of $76,851.20.

Cytokinetics Trading Up 0.1 %

Shares of NASDAQ CYTK opened at $54.93 on Thursday. The stock has a fifty day moving average price of $55.25 and a 200 day moving average price of $67.96. The company has a market cap of $5.76 billion, a P/E ratio of -10.17 and a beta of 0.75. Cytokinetics, Incorporated has a 12-month low of $25.98 and a 12-month high of $110.25.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.17). The business had revenue of $0.84 million for the quarter, compared to the consensus estimate of $0.91 million. Cytokinetics’s revenue was down 81.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.38) earnings per share. On average, sell-side analysts forecast that Cytokinetics, Incorporated will post -4.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System boosted its position in Cytokinetics by 0.8% in the 4th quarter. Maryland State Retirement & Pension System now owns 35,637 shares of the biopharmaceutical company’s stock valued at $2,975,000 after buying an additional 278 shares during the last quarter. Quadrant Capital Group LLC lifted its position in shares of Cytokinetics by 9.6% during the fourth quarter. Quadrant Capital Group LLC now owns 3,268 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 287 shares during the last quarter. First Bank & Trust lifted its position in shares of Cytokinetics by 4.7% during the second quarter. First Bank & Trust now owns 6,757 shares of the biopharmaceutical company’s stock worth $366,000 after purchasing an additional 303 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of Cytokinetics by 94.1% during the first quarter. Fifth Third Bancorp now owns 656 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 318 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its position in shares of Cytokinetics by 2.0% during the fourth quarter. Mutual of America Capital Management LLC now owns 17,162 shares of the biopharmaceutical company’s stock worth $1,433,000 after purchasing an additional 337 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have weighed in on CYTK. Barclays cut their price target on Cytokinetics from $100.00 to $95.00 and set an “overweight” rating for the company in a report on Thursday, May 23rd. JMP Securities dropped their price objective on Cytokinetics from $106.00 to $78.00 and set a “market outperform” rating for the company in a report on Tuesday, May 28th. Bank of America dropped their price objective on Cytokinetics from $70.00 to $60.00 and set a “neutral” rating for the company in a report on Thursday, May 23rd. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Cytokinetics in a report on Monday, June 17th. Finally, Oppenheimer dropped their price objective on Cytokinetics from $107.00 to $106.00 and set an “outperform” rating for the company in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Cytokinetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.06.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.